Drug manufacturer Merck announced on Friday that it will soon seek authorization from the Food and Drug Administration (FDA) for approval of the first COVID-19 antiviral drug that can be administered as a pill.
The drug — known as molnupiravir — works by stopping the virus from being able to replicate in a person’s body. A patient who has received an early coronavirus diagnosis would take four capsules twice a day for five days as treatment.
When given to higher-risk patients early on in their infection during clinical trials, the drug has cut coronavirus death and hospitalization rates in half within just five days of starting the daily pill regimen.
The results of the clinical trial are immensely promising to those monitoring it — so much so that an independent group of medical experts who were supervising the trial stopped it early because its efficacy rate was so high.
Other treatment options remain much more effective at preventing infection or treating those who are diagnosed with coronavirus. For example, monoclonal antibody treatments are shown to prevent the need for hospitalization or the chance of death by around 70 percent. Vaccinations against COVID-19 have had even higher rates of success in preventing contraction of and hospitalization for the virus.
But monoclonal antibody treatments are expensive, and access to vaccines is limited in many parts of the globe.
“I think it will translate into many thousands of lives being saved worldwide, where there’s less access to monoclonal antibodies, and in this country, too,” said Robert Shafer, an infectious disease specialist at Stanford University speaking to The New York Times.
“This could turn out to be one of the most important advances to counter Covid,” tweeted Eric Topol, an American cardiologist, scientist and author.
Though the availability of a pill to treat COVID may result in vaccine skeptics thinking they don’t need to get vaccinated to protect themselves from contracting the virus, experts say that preventive measures remain the best way to manage the pandemic, rather than treatment methods.
According to a recent Economist/YouGov poll, 17 percent of Americans still say they will never get vaccinated, while around 11 percent say they’re still unsure.
“We love having more treatments available, but prevention is the first goal,” said William Schaffner, an infectious disease expert at Vanderbilt University who spoke to the Associated Press about the Merck medication. “Vaccination continues to be the foundation of how we can get ahead of COVID.”
Help us Prepare for Trump’s Day One
Trump is busy getting ready for Day One of his presidency – but so is Truthout.
Trump has made it no secret that he is planning a demolition-style attack on both specific communities and democracy as a whole, beginning on his first day in office. With over 25 executive orders and directives queued up for January 20, he’s promised to “launch the largest deportation program in American history,” roll back anti-discrimination protections for transgender students, and implement a “drill, drill, drill” approach to ramp up oil and gas extraction.
Organizations like Truthout are also being threatened by legislation like HR 9495, the “nonprofit killer bill” that would allow the Treasury Secretary to declare any nonprofit a “terrorist-supporting organization” and strip its tax-exempt status without due process. Progressive media like Truthout that has courageously focused on reporting on Israel’s genocide in Gaza are in the bill’s crosshairs.
As journalists, we have a responsibility to look at hard realities and communicate them to you. We hope that you, like us, can use this information to prepare for what’s to come.
And if you feel uncertain about what to do in the face of a second Trump administration, we invite you to be an indispensable part of Truthout’s preparations.
In addition to covering the widespread onslaught of draconian policy, we’re shoring up our resources for what might come next for progressive media: bad-faith lawsuits from far-right ghouls, legislation that seeks to strip us of our ability to receive tax-deductible donations, and further throttling of our reach on social media platforms owned by Trump’s sycophants.
We’re preparing right now for Trump’s Day One: building a brave coalition of movement media; reaching out to the activists, academics, and thinkers we trust to shine a light on the inner workings of authoritarianism; and planning to use journalism as a tool to equip movements to protect the people, lands, and principles most vulnerable to Trump’s destruction.
We urgently need your help to prepare. As you know, our December fundraiser is our most important of the year and will determine the scale of work we’ll be able to do in 2025. We’ve set two goals: to raise $104,000 in one-time donations and to add 1340 new monthly donors by midnight on December 31.
Today, we’re asking all of our readers to start a monthly donation or make a one-time donation – as a commitment to stand with us on day one of Trump’s presidency, and every day after that, as we produce journalism that combats authoritarianism, censorship, injustice, and misinformation. You’re an essential part of our future – please join the movement by making a tax-deductible donation today.
If you have the means to make a substantial gift, please dig deep during this critical time!
With gratitude and resolve,
Maya, Negin, Saima, and Ziggy